Liver cancer is not rare. It ranks as the sixth most commonly diagnosed cancer worldwide, with roughly 865,000 new cases identified globally in 2022. In the United States alone, an estimated 116,500 people were living with liver or bile duct cancer in 2023. By any medical definition, those numbers place it firmly among common cancers.
How Common Liver Cancer Is Globally
Liver cancer is the sixth most frequently diagnosed cancer in the world and the third leading cause of cancer-related death. That gap between how often it’s diagnosed and how often it kills tells an important story: liver cancer tends to be caught late and is difficult to treat once it has spread. In 2022, approximately 865,269 people were diagnosed with it worldwide, and nearly 758,000 died from it the same year.
Incidence varies dramatically by region. Rates are highest in East Asia and sub-Saharan Africa, largely driven by chronic hepatitis B infection, which remains widespread in those areas. In the United States and Western Europe, rates are lower overall but have been climbing for decades, fueled by hepatitis C, alcohol-related liver disease, and a rising tide of fatty liver disease linked to obesity.
Who Gets Liver Cancer Most Often
Men develop liver cancer at two to eight times the rate women do, a disparity that holds across every geographic region, time period, and racial or ethnic group studied. The reasons aren’t fully understood, but hormonal differences, higher rates of hepatitis infection, and greater alcohol consumption in men all play a role.
In the United States, Hispanic men have seen the steepest rise in incidence, with rates climbing roughly 4.7% per year since 2000. Rates have been increasing across nearly all racial and ethnic groups, with one notable exception: Asian and Pacific Islander Americans, who have seen rates hold steady or decline, likely reflecting better hepatitis B vaccination and treatment in those communities. Among younger adults under 50, rates have actually fallen since the mid-2000s, with the sharpest drops among middle-aged Black Americans.
Types of Primary Liver Cancer
Not all liver cancers are the same. The most common form, hepatocellular carcinoma, accounts for 75 to 85% of primary liver cancers. It starts in the main liver cells and is strongly linked to chronic liver damage from hepatitis, alcohol, or fatty liver disease. The second most common type, intrahepatic cholangiocarcinoma, makes up 10 to 15% of cases and begins in the bile ducts inside the liver. It behaves differently, responds to different treatments, and generally carries a worse prognosis.
It’s also worth noting that many cancers found in the liver didn’t start there. Metastatic liver cancer, where tumors spread to the liver from the colon, breast, lung, or another organ, is actually more common than primary liver cancer. When people talk about liver cancer statistics, they’re typically referring to cancers that originated in the liver itself.
Why It’s Often Found Late
The liver has no pain receptors inside its tissue. Small tumors produce no symptoms, and the organ can continue functioning normally even when a significant portion is affected. By the time symptoms appear, such as unexplained weight loss, upper abdominal pain, yellowing of the skin, or a feeling of fullness after small meals, the cancer has often grown large or spread beyond the liver. This is a major reason survival rates remain low compared to many other common cancers.
Catching liver cancer early dramatically changes the outlook. When confined to the liver, treatment options like surgical removal or transplant can be curative. Once the cancer reaches nearby lymph nodes or distant organs, those options narrow considerably.
Screening for People at High Risk
Because liver cancer develops silently, routine screening matters for people with known risk factors. Current guidelines from the American Association for the Study of Liver Diseases recommend that high-risk individuals get screened every six months using a combination of abdominal ultrasound and a blood test that measures a protein called AFP.
The groups recommended for regular screening include:
- People with cirrhosis from any cause, including alcohol use, hepatitis, or fatty liver disease
- People with chronic hepatitis B, even without cirrhosis, particularly men over 40 and women over 50 from regions where hepatitis B is common
- People of African descent with hepatitis B, who are recommended to start screening at an earlier age
- Anyone with a family history of liver cancer
- Patients listed for liver transplant, since finding early-stage cancer changes their transplant priority
People with advanced cirrhosis who would not be candidates for transplant are generally not enrolled in screening programs, since the treatment options available to them are limited regardless of when a tumor is found.
The Bigger Picture on Rarity
Liver cancer is less common than breast, lung, prostate, or colorectal cancer. That relative ranking sometimes creates a perception that it’s rare, but the numbers don’t support that label. A rare disease in the United States is officially defined as one affecting fewer than 200,000 people at any given time. With over 116,000 people living with liver cancer and tens of thousands of new diagnoses each year, it sits just below that threshold but remains one of the faster-growing cancers in the country. Globally, with nearly 900,000 new cases annually, calling it rare would be misleading. It is a common cancer with an outsized death toll, largely because it develops in people who already have damaged livers and because it’s so often found too late for the most effective treatments.